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Abstract: INTRODUCTION Quality indicators and pay-for-performance schemes aim to improve pro-
cesses and outcomes in clinical practice. However, general practitioner and patient characteristics in-
fluence quality indicator performance. In Switzerland, no data on the pay-for-performance approach
exists and the use of quality indicators has been marginal. The aim of this study was to describe quality
indicator performance in diabetes care in Swiss primary care and to analyze associations of practice,
general practitioner and patient covariates with quality indicator performance. METHODS For this
cross-sectional study, we used medical routine data from an electronic medical record database. Data
from 71 general practitioners and all their patients with diabetes were included. Starting in July 2018,
we retrieved 12-month retrospective data about practice, general practitioner and patient characteristics,
laboratory values, comorbidities and co-medication. Based on this data, we assessed quality indicator
performance of process and intermediate outcomes for glycated hemoglobin, blood pressure, cholesterol
and associations of practice, general practitioner and patient characteristics with individual and cumu-
lative quality indicator performance. We calculated odds ratios (OR) and 95% confidence intervals (CI)
using regression methods. RESULTS We assessed 3,383 patients with diabetes (57% male, mean age 68.3
years). On average, patients fulfilled 3.56 (standard deviation: 1.89) quality indicators, whereas 17.2%
of the patients fulfilled all six quality indicators. On practice and general practitioner level, we found
no associations with cumulative quality indicator performance. On patient level, gender (ref = male)
(OR: 0.83, CI: 0.78-0.88), number of treating general practitioners (OR: 0.94, CI: 0.91-0.97), number of
comorbidities (OR: 1.43, CI: 1.38-1.47) and number of consultations (OR: 1.02, CI: 1.02-1.02) were asso-
ciated with cumulative quality indicator performance. CONCLUSION The influence of practice, general
practitioner and patient characteristics on quality indicator performance was surprisingly small and room
for improvement in quality indicator performance of Swiss general practitioners seems to exist in diabetes
care.
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Quality indicators and pay-for-performance schemes aim to improve processes and out-
comes in clinical practice. However, general practitioner and patient characteristics influ-
ence quality indicator performance. In Switzerland, no data on the pay-for-performance
approach exists and the use of quality indicators has been marginal. The aim of this study
was to describe quality indicator performance in diabetes care in Swiss primary care and to
analyze associations of practice, general practitioner and patient covariates with quality indi-
cator performance.
Methods
For this cross-sectional study, we used medical routine data from an electronic medical
record database. Data from 71 general practitioners and all their patients with diabetes were
included. Starting in July 2018, we retrieved 12-month retrospective data about practice,
general practitioner and patient characteristics, laboratory values, comorbidities and co-
medication. Based on this data, we assessed quality indicator performance of process and
intermediate outcomes for glycated hemoglobin, blood pressure, cholesterol and associa-
tions of practice, general practitioner and patient characteristics with individual and cumula-
tive quality indicator performance. We calculated odds ratios (OR) and 95% confidence
intervals (CI) using regression methods.
Results
We assessed 3,383 patients with diabetes (57% male, mean age 68.3 years). On aver-
age, patients fulfilled 3.56 (standard deviation: 1.89) quality indicators, whereas 17.2% of
the patients fulfilled all six quality indicators. On practice and general practitioner level,
we found no associations with cumulative quality indicator performance. On patient level,
gender (ref = male) (OR: 0.83, CI: 0.78–0.88), number of treating general practitioners
(OR: 0.94, CI: 0.91–0.97), number of comorbidities (OR: 1.43, CI: 1.38–1.47) and number
of consultations (OR: 1.02, CI: 1.02–1.02) were associated with cumulative quality indica-
tor performance.
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Conclusion
The influence of practice, general practitioner and patient characteristics on quality indicator
performance was surprisingly small and room for improvement in quality indicator perfor-
mance of Swiss general practitioners seems to exist in diabetes care.
Introduction
The use of quality indicators (QI) and contingent incentives aim to improve processes and
outcomes in clinical practice. However, whether QI performance is modifiable by introducing
a pay-for performance (P4P) scheme is still unclear [1–4]. Previous studies showed that P4P
programs’ effectiveness highly depend on type of health care system, investigated QI, study
participants, patient population and the level of payment [2, 5, 6]. A systematic review [7] con-
cluded that financial incentives targeting process and intermediate outcome indicators yield
the highest effect, as they can be directly influenced by general practitioners (GP). In diabetes,
which is one of the most common diseases for assessing quality of care, the most frequent pro-
cess and intermediate outcome QIs are for glycated hemoglobin (HbA1c), blood pressure (BP)
and serum cholesterol levels. From literature, we know that not only practice and GP, but also
patient characteristics influence QI performance [8–12]. Case-mix adjustments are therefore
often used to control for these mechanisms. However, the case-mix adjustments used and
their effect on QI performance vary widely across studies [13–15].
In Switzerland, the use of QIs, especially in primary care, has been marginal. No P4P
approach exists and no case-mix adjustments have been investigated [16]. Currently, a ran-
domized controlled trial (RCT) testing the P4P approach in Swiss primary care using clinical
routine data is ongoing [17]. The baseline data of this trial offer the opportunity to study the
characteristics and QI performance of the study population and to analyze associations of
practice, GP and patient covariates with QI performance.
Methods
Study design and setting
For this cross-sectional study we used baseline data collected within a cluster randomized
controlled trial (trial registration number: ISRCTN13305645) [17]. Unit of cluster ran-
domization was at practice level. The baseline assessment covered 12 months retrospec-
tively (Fig 1). The trial was launched within the family medicine international
classification of primary care (ICPC) research using electronic medical records (EMR)
(FIRE) database of the Institute of Primary Care of the University of Zurich [18]. Up to
June 2018, more than 400 GPs from the German-speaking area of Switzerland participated
in the FIRE project. The participants contribute anonymized data containing the follow-
ing components: administrative information, vital signs, laboratory values, medication
data and diagnostic codes coded according to ICPC-2 [19]. Up to June 2018, information
from more than 500,000 patients and 5 million consultations are available. Further, at
individual project entry the participating GPs manually provided additional information
concerning structural details to the study nurse of the research team. According to the
local ethics committee of the canton of Zurich, the project does not fall under the scope of
the law on human research and therefore no ethical consent was necessary (BASEC-Nr.
Req-2017-00797).
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Participants
For the trial, the following data availability and data quality criteria had to be fulfilled on GP level:
a) continuous data delivery since January 2017, b) delivering HbA1c and BP values in more than
10% of their patients with diabetes, and c) consulting a minimum of five patients with diabetes.
In June 2018, the eligible GPs received an invitation to participate in the study. Per practice, mul-
tiple GPs were contacted if data availability and data quality criteria were fulfilled (Fig 1). From
the participating GPs, all patients diagnosed with diabetes at least 4 months before the baseline
date were subsequently identified according to at least one of the following criteria:
1. Patients with ICPC-2 codes T89 (insulin dependent diabetes mellitus) and T90 (insulin
independent diabetes mellitus)
Fig 1. Flowchart. Study design including inclusion/exclusion criteria, FIRE = Family medicine ICPC research using
electronic medical records; GP = General practitioner.
https://doi.org/10.1371/journal.pone.0232686.g001
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2. Patients with antidiabetic medication (oral antidiabetics and/or insulin) according to the
anatomical therapeutic chemical (ATC) classification system (A10A, A10B, A10X) [20]
Database query and variables
From the included GPs, we retrieved demographic (year of birth, gender) and work setting
related data (practice location to assess urbanity [21], practice type (single or group practice),
physician’s network participation). From the included patients we retrieved following data: a)
demographics (year of birth, gender), b) laboratory values(HbA1c, cholesterol) and vital signs
(BP, body mass index (BMI) recorded within the observation period, c) prescription of rele-
vant medication (insulin, oral anti-diabetic medication, anti-hypertensive medication, anti-
thrombotic medication, lipid lowering medication) recorded within the observation period, d)
presence of comorbidities relevant for diabetes (obesity, arterial hypertension, hyperlipidemia,
microvascular complications (chronic kidney disease stage 3a or higher, peripheral vascular
disease, retinopathy or neuropathy) and macrovascular complications (coronary heart disease
(CHD), chronic heart failure (CHF), stroke) available in the full patient history in the FIRE
database. Detailed information about the identification scheme for comorbidities is depicted
in the S1 Table. For each patient, we determined the baseline performance (fulfilled/not ful-
filled) based on the QI defined in the P4P trial [22, 23]. QIs are listed in Table 1. Furthermore,
we calculated the cumulative QI performance, which is the number of fulfilled QIs per patient.
Objectives
Objectives of the current study are:
• Description of the study population characteristics, including baseline QI performance
• Examination of the associations of practice, GP and patient covariates with QI performance
Statistical analysis
We presented categorical data as frequencies and percentages, continuous variables as means and
standard deviations (SD) or median and interquartile range (IQR), as appropriate. Overall QI per-
formances are expressed as percentage of patients meeting the indicator (numerator), in reference
to all eligible patients (denominator). We used hierarchical multivariable logistic regression mod-
els, with the practice and the GP nested within practices as random variables, to examine the inde-
pendent association of each QI performance on patient level with practice (practice location,
practice type), GP (age, sex, physician’s network participation) and patient characteristics (age,
sex, number of comorbidities, number of consultations, number of consulted GPs). Number of
medications and BMI were not considered as covariates for the regression model, since they were
Table 1. Quality indicators used to assess performance.
Process indicators Outcome indicators
Blood
pressure
Proportion of patients with diabetes with at least one blood pressure
measure-meant in the preceding 12 months.
Proportion of patients with diabetes with a blood pressure
measurement< 140/85 mmHg in the preceding 12 months.
HbA1c Proportion of patients with diabetes with at least one measurement of
HbA1c in the preceding 12 months.
Proportion of patients with diabetes with HbA1c levels< 7.5% in the
preceding 12 months.
Cholesterol Proportion of patients with diabetes with at least one cholesterol
measurement in the preceding 12 months.
Proportion of patients with diabetes with total cholesterol < 5 mmol/l in the
preceding 12 months.
HbA1c = measure for glycated hemoglobin;
https://doi.org/10.1371/journal.pone.0232686.t001
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used to identify certain comorbidities. We ran the model for each of the six QIs. The same model
variables were used in a hierarchical multivariable binomial logistic regression model to assess the
association for the cumulative QI performance, whereas the dependent variable was defined as
the cumulative QI performance. We reported odds ratios (OR) and 95% confidence intervals (CI)
for each factor included in the model and used random effects to study variance on practice and
GP level. All analyses were performed using the statistical software R (version 3.5.0) [24].
Results
Sample characteristics
We included 71 GPs from 43 practices in the study. We enrolled 61 GPs in cohort 1, starting
in July 2018, whereas 10 GPs were enrolled in a second cohort, starting in September 2018.
Their mean age was 52 years (SD 9.3), 72% were male and 92% worked in a group practice.
They practiced in 83% in an urban setting and 93% were member of a physician’s network.
With the participating GPs, a total of 3,833 patients with diabetes were included. The median
number of patients with diabetes per GP was 44 (IQR: 28–79), corresponding to 5% (IQR: 3%
- 7%) of GP’s patient list size. These patients were 57% male and had a mean age of 68.3 years
(SD 13.4). The first record of diabetes within the database was on average 2.6 years (IQR: 1.3–
6.2) before baseline assessment.
93.8% of patients had at least one, 37.9% three or more comorbidities. The most frequent
comorbidity was arterial hypertension, followed by hyperlipidemia and obesity (see Table 2 for
exact numbers on comorbidities). Diabetes-associated microvascular complications were identi-
fied in 18.3% of patients, macrovascular complications in 10.0% (see Table 2 for exact numbers).
Treatment and disease characteristics
On average, patients had eight consultations (IQR: 5–15) at the GPs’ practice in the 12 months
preceding baseline. In those consultations, average numbers of BP measurements, HbA1c test-
ing, cholesterol testing and BMI measurements, as well as the parametric values thereof are
reported in Table 2. Regarding anti-diabetic therapy, we found that 72.7% of patients received
a therapy; most often oral medication only, followed by the combination of an oral and an
insulin therapy and insulin only (see Table 2 for the exact numbers). Moreover, 47.9% of
patients received an antihypertensive agent, 40.2% antiplatelet therapy and anticoagulants, and
35.5% lipid-lowering therapy. For proportions of patients achieving the defined QIs see
Table 3. On average, patients fulfilled 3.6 (SD: 1.9) QIs, whereas 17.2% of the patients fulfilled
all QIs.
Associations with QI performance
The regression model revealed the following results: for practice and GP characteristics, we
did not find evidence of significant associations with QI performance (Table 4), except for
female GPs measuring BP more often (OR 1.75 95% CI 1.03–2.98) and older GPs achieving BP
target level in a larger share of their patients (OR 1.23 95% CI 1.02–1.49). On patient level, age
had no influence on achieving BP QIs (process indicator: OR 1.06 95% CI 0.99–1.13, outcome
indicator: OR 1.00 95% CI 0.95–1.06). Higher age was significantly associated with achieving
the HbA1c QIs more often (process indicator: OR 1.07 95% CI 1.01–1.14, outcome indicator:
OR 1.10 95% CI 1.04–1.16), but with achieving the cholesterol QIs less often (process indica-
tor: OR 0.86 95% CI 0.81–0.91, outcome indicator: OR 0.92 95% CI 0.86–0.97). Female gender
was also significantly associated with achieving the cholesterol QIs more often (process indica-
tor: OR 0.73 95% CI 0.63–0.85, outcome indicator: OR 0.5 95% CI 0.42–0.58). For patients
PLOS ONE Quality performance and associated factors in diabetes care
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with an increasing number of diabetes-relevant comorbidities, the QIs were more often ful-
filled (see Table 4 for OR & 95% CI), whereas the number of consultations only had a positive
effect on fulfilling the BP and HbA1c QIs (Table 4). With an increasing number of GPs provid-
ing care for the same diabetes patient, the chances in achieving process indicators decreased
(Table 4). Number of years since diabetes diagnosis was significantly associated with achieving
HbA1c outcome QI less often (OR 0.96 95% CI 0.93–0.99), but achieving cholesterol outcome
QI more often (OR 1.08 95% CI 1.04–1.12). Associations of the cumulative QIs are presented
in Fig 2.
Hierarchical random effects for GPs nested in practices showed, that the variation on prac-
tice and GP level are considerable but different for each QI (see S1–S6 Figs). For the model
Table 2. Patient, treatment and disease characteristics.
Median, mean or n IQR, SD or %
Patient characteristics
Male gender 2198 57.3
Age at baseline (years) 68.3 13.4
First record of diabetes before baseline (years) 2.6 1.3–6.2
Diabetes associated Comorbidities
Arterial hypertension 3322 86.7
Hyperlipidemia 2262 59.0
Obesity 1589 41.5
Chronic kidney disease 454 11.8
Peripheral vascular disease 134 3.5
Neuropathy 100 2.6
Retinopathy 14 0.4
Coronary heart disease 234 6.1
Heart failure 83 2.2
Stroke 67 1.7
Treatment and disease characteristics
Number of consultations 8 5–15
Number of BP measurements 2.3 2.6
Number of HbA1c measurements 2.1 1.5
Number of cholesterol measurements 0.7 0.9
Number of BMI measurements 1.2 1.6
Systolic BP value (mmHg) 135.9 126.5–146.1
Diastolic BP value (mmHg) 80 73.7–85.0
HbA1c value (%) 6.8 6.3–7.5
Cholesterol value (mmol/l) 4.5 3.8–5.4
BMI value (kg/m2) 29.53 26.3–33.3
Diabetes associated medication
Oral anti-diabetic medication 1978 51.6
Insulin 278 7.5
Combination of oral medication and insulin 520 13.6
Antihypertensive medication 1837 47.9
Antiplatelet therapy and anticoagulants 1542 40.2
Lipid lowering medication 1359 35.5
IQR = interquartile range; SD = standard deviation; BP = blood pressure; HbA1c = measure for glycated hemoglobin;
BMI = body mass index;
https://doi.org/10.1371/journal.pone.0232686.t002
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with the cumulative QI, only little variation was associated with the practice level and the
unexplained variation was associated with the GP level (see S7 Fig).
Discussion
In this study, we explored associations of practice, GP and patient characteristics with QI per-
formance. We found no substantial effect from GP and practice characteristics on QI perfor-
mance, whereas several patient characteristics had a small effect.
The patient population included in our study is highly comparable to the patient population
of a recent RCT and a cross-sectional study in Swiss primary care [25, 26] in terms of age, gen-
der, comorbidities and consultation count. In terms of age and gender, our study population
was also highly comparable to other European diabetes populations, whereas in terms of
comorbidities our population had less micro- and macro-vascular diseases [27]. Number of
years since diabetes diagnosis was much shorter in our study, which is explained by the fact
limited data were available from before GPs participated in the FIRE project.
Comparing QI performances from our study with previous studies is fairly challenging, due
to heterogeneity regarding study type, patient population, clinical thresholds and underlying
financial incentives of different health care systems [13, 27, 28]. The proportions of patients
fulfilling the process and outcome indicators for BP and HbA1c were highly comparable to the
methodological similar study of van Doorn-Klomberg et al. 2015 [13], whereas the European
cross-sectional study of Stone et al. 2013 [27] reported process indicators above 90%. A recent
Swiss study based on insurance claims data found slightly higher annual rates for HbA1c and
total cholesterol measurements [29]. When comparing to the Swiss quality and outcome feasi-
bility study of Djalali et al. 2014, which based on the same EMR database, an improvement for
each QI was achieved [16]. However, QI performance in our study still showed room for
improvement, especially for outcome indicators. Possible reasons for such poor performances
might be clinical inertia to intensify treatment, poor patient adherence, or failure in structural
data capturing [16, 30, 31].
Regression analysis revealed that included characteristics had no or very little effect on pro-
cess and outcome indicators. Most significant effects were found on patient level, and the
greatest positive effect on QI performance was an increasing number of diabetes-relevant
comorbidities. More intensive consultations or an increased awareness and risk factor man-
agement in multimorbid patients with certain comorbidities might explain this finding [32,
Table 3. Proportion of patients achieving the defined quality indicators.
Description Quality indicator
performance % (n)
Proportion of patients with diabetes with at least one blood pressure measurement
in the preceding 12 months.
75.6 (2,899)
Proportion of patients with diabetes with a blood pressure measurement< 140/85
mmHg in the preceding 12 months.
50.6 (1,941)
Proportion of patients with diabetes with at least one measurement of HbA1c in
the preceding 12 months.
80.4 (3,082)
Proportion of patients with diabetes with HbA1c levels< 7.5% in the preceding 12
months.
66.3 (2,543)
Proportion of patients with diabetes with at least one cholesterol measurement in
the preceding 12 months.
49.3 (1,891)
Proportion of patients with diabetes with total cholesterol < 5 mmol/l in the
preceding 12 months.
33.5 (1,285)
HbA1c = measure for glycated hemoglobin;
https://doi.org/10.1371/journal.pone.0232686.t003
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33]. However, the finding is contradictory to the guidelines of the American Diabetes Associa-
tion, recommending a more lenient therapy in multimorbid patients [34]. The same is recom-
mended for disease duration, which we could confirm being associated with lower rates of
target value performances for HbA1c. Also notifiable are gender differences regarding QI per-
formance. Female patients had significantly fewer cholesterol measurements and if measured,
Table 4. Results of hierarchical multivariable regression analysis of quality indicator performance.
OR 95% CI P-value OR 95% CI P-value
Blood pressure
Process indicator Outcome indicator
Practice type (ref = group practice) 2.07 0.86–4.97 0.10 1.41 0.75–2.64 0.29
Practice location (ref = urban) 0.90 0.47–1.74 0.76 0.83 0.51–1.35 0.45
Network participation (ref = yes) 0.74 0.30–1.84 0.52 1.09 0.55–2.17 0.81
GP gender (ref = male) 1.75 1.03–2.98 <0.05 1.38 0.93–2.05 0.11
GP age (per 10 years) 1.11 0.86–1.43 0.43 1.23 1.02–1.49 <0.05
Patient gender (ref = male) 0.90 0.76–1.07 0.25 1.00 0.87–1.15 0.98
Patient age (per 10 years) 1.06 0.99–1.13 0.09 1.00 0.95–1.06 0.93
Number of GPs 0.89 0.82–0.96 <0.01 0.98 0.92–1.05 0.58
Number of consultations 1.05 1.04–1.07 <0.001 1.06 1.05–1.07 <0.001
Number of comorbidities 1.76 1.61–1.93 <0.001 1.15 1.07–1.23 <0.001
Number of years since diagnosis 0.98 0.94–1.01 0.21 1.02 0.98–1.05 0.32
HbA1c
Process indicator Outcome indicator
Practice type (ref = group practice) 0.71 0.39–1.31 0.28 0.75 0.46–1.24 0.26
Practice location (ref = urban) 0.75 0.45–1.23 0.26 1.05 0.71–1.56 0.81
Network participation (ref = yes) 0.94 0.48–1.82 0.85 0.78 0.45–1.35 0.38
GP gender (ref = male) 1.39 0.94–2.05 0.10 1.32 0.93–1.87 0.12
GP age (per 10 years) 0.90 0.74–1.08 0.24 0.95 0.81–1.11 0.51
Patient gender (ref = male) 0.85 0.72–1.02 0.08 0.91 0.79–1.05 0.19
Patient age (per 10 years) 1.07 1.01–1.14 <0.05 1.10 1.04–1.16 <0.001
Number of GPs 0.89 0.82–0.97 <0.01 0.96 0.90–1.03 0.25
Number of consultations 1.05 1.04–1.07 <0.001 1.02 1.01–1.03 <0.001
Number of comorbidities 1.83 1.66–2.01 <0.001 1.48 1.38–1.60 <0.001
Number of years since diagnosis 0.99 0.95–1.03 0.66 0.96 0.93–0.99 <0.01
Cholesterol
Process indicator Outcome indicator
Practice type (ref = group practice) 1.17 0.54–2.56 0.69 1.01 0.47–2.17 0.98
Practice location (ref = urban) 0.96 0.50–1.84 0.90 1.24 0.65–2.35 0.51
Network participation (ref = yes) 0.59 0.25–1.41 0.24 0.60 0.26–1.41 0.25
GP gender (ref = male) 1.14 0.75–1.74 0.54 1.20 0.82–1.76 0.34
GP age (per 10 years) 0.81 0.66–1.01 0.06 0.86 0.71–1.04 0.12
Patient gender (ref = male) 0.73 0.63–0.85 <0.001 0.50 0.42–0.58 <0.001
Patient age (per 10 years) 0.86 0.81–0.91 <0.001 0.92 0.86–0.97 <0.01
Number of GPs 0.89 0.83–0.95 <0.001 0.92 0.85–0.98 <0.05
Number of consultations 1.00 0.99–1.00 0.27 1.01 1.00–1.01 0.12
Number of comorbidities 1.89 1.75–2.04 <0.001 1.40 1.30–1.51 <0.001
Number of years since diagnosis 1.02 0.99–1.06 0.18 1.08 1.04–1.12 <0.001
OR = Odds ratio; CI = confidence interval; ref = reference; GP = general practitioner.
https://doi.org/10.1371/journal.pone.0232686.t004
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a higher level. This is highly congruent to recent results investigating gender disparities in dia-
betes care and revealing gender disparities in risk factor management, prescribing behavior
and guideline adherence [35, 36].
Number of consultations was positively associated with QI performance. Van Doorn-
Klomberg interpreted similar results in their study as a measure of patients’ adherence to a
treatment plan, based on an automatic invitation for 3-monthly consultations [13]. In Switzer-
land, the study of Frei et al. 2013 also found no association with consultation count, which
might be due to the fact that in Switzerland a structured invitation mechanism for follow-up
appointments is uncommon. Another known factor associated with increased quality of diabe-
tes care is continuity of care [37, 38]. We did not explicitly measure continuity of care, but we
found a negative association between number of treating GPs and all three process indicators,
and a negative association with the outcome indicator of cholesterol. This finding is not
completely in line with Lustman et al. 2016 [37], reporting a positive effect of continuity of
care on the major clinical outcomes. Furthermore, we know from literature, that several other
patient factors, such as ethnicity/culture, financial resources, beliefs, knowledge and other per-
son-related characteristics, influence diabetes care [12, 39]. Unfortunately, information on
these characteristics were not available within the study setting.
In our study, female GPs had a small but positive effect on QI performance, which is repeat-
edly observed [8, 14]. However, our model also revealed that variation exists between practices
and GPs, which cannot be explained by our model. This might be due to a lack of important
information about practice and GP characteristics, such as practice culture, working style and
accessibility of disease management tools [10, 12, 40]. Overall, it is in line with previous
Fig 2. Associations with cumulative quality indicator performances. ref = reference; GP = General practitioner.
https://doi.org/10.1371/journal.pone.0232686.g002
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research, that organization, GP and patient characteristics can only explain small proportions
of variation in diabetes care [10, 11].
Strengths and limitations of this study
Amajor strength of our study is the relevance of the disease under study: Diabetes is highly
prevalent and associated with high morbidity, mortality and costs [41]. Furthermore, we did
not allow for exclusion of individual patients and included the entire spectrum of patients with
diabetes, reflecting the everyday situation of a GP. We were therefore able to show high gener-
alizability of our data. Another major strength of our study is the wide GP coverage of the
FIRE database. FIRE is to date the only database of clinical routine data in Swiss primary care
and covers about 10% of GPs practicing in the German-speaking area of Switzerland [42]. GPs
participating in the P4P trial are representative for the Swiss GPs in terms of age, but are more
often male than the average Swiss GP. However, GPs participating in the FIRE project and
additionally in the P4P trial might not be completely representative, as those voluntarily partic-
ipating in research projects are highly motivated and better performing [43].
This study faces methodological drawbacks commonly present in EMR database studies, i.e.
the cross-sectional design, data structure and potential missing data. Not all diabetes-specific
comorbidities can be depicted in the FIRE database, due to data structure in the EMR, which
does not allow for structural recording of several factors, such as lifestyle, hereditary factors,
severity and duration. Duration of diabetes was approximated by using the first record as the
onset of diabetes. However, this might highly underestimate the duration, as we have no infor-
mation from the patient before the GP participated in the FIRE project. Furthermore, informa-
tion about socioeconomic status and other person- related characteristics are not recorded in
the EMR. Missing data is the largest source of bias for our study, as we cannot distinguish
between real missing data (not measured) and technical missing data (not available for FIRE
due to data capturing or transmission problems for example). This issue is of major concern for
the QI measures and comorbidity identification, where we assumed that if there was no positive
record, no measurement or disease was present. The proportions not fulfilling the process indi-
cators disclose the maximal percentage of missing data for QI measures. We tried to minimize
the amount of missing data by setting a minimum standard of data availability for each GP to
be contacted for recruitment. Further limitations of our study are that a few patients were not
diagnosed with diabetes over the entire observation period, as the identification needed to be
present four months prior to baseline. In addition, type 1 and type 2 patients cannot be fully dis-
tinguished due to data structure. However, from the prescription of medications one can con-
clude that the majority of patients included were patients with type 2 diabetes.
Conclusion
The influence of practice, GP and patient characteristics on QI performance was surprisingly
small and room for improvement in QI performance of Swiss GPs seems to exist in diabetes
care. We believe that improving the quality of QI measurements is an important step towards
correctly assessing quality of care in primary care. In order to achieve a valid assessment of
quality of care, it is essential to comprehensively include all potentially meaningful provider
and patient characteristics within routine data collection. Moreover, it will be of particular
interest to see whether the P4P approach leads to higher QI performance.
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